 A final study extension provided all study participants from both treatment regimens the option to switch their respective treatments to the 1-pill regimen of for a further 96 weeks up to a total study duration of 240 weeks 5 years to further assess the efficacy and safety of ART regimen simplification. At sites in France, the study was extended by a further 48 weeks Year 6 or until ATR became commercially available whichever happened first; once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study. 